Class 16
San Francisco – Batch 16
Undo See the concurrent NY batch Contact Us for an
Early Intro
Antarka
Repairing the past, protecting the future of your skin.
Signed partnerships with 5 key strategics in 4 months within their batch.

Antarka is redefining skincare with next-generation photolyases—specialized enzymes that repair DNA damage caused by UV radiation. Sourced from Antarctic microorganisms, they deliver 100% DNA repair efficacy, offering the best-in-class solution to combat the root cause of skin aging: DNA damage.

Stefano Valdesolo, CEO & Co-Founder
"From Antarctica’s harshest conditions, we bottled nature’s most powerful defenses to transform skin health through DNA repair."
Antarka has raised $750,000 from SOSV's IndieBio and others.
Antarka
Stefano Valdesolo, CEO & Co-Founder
"From Antarctica’s harshest conditions, we bottled nature’s most powerful defenses to transform skin health through DNA repair."
Antarka has raised $750,000 from SOSV's IndieBio and others.
Fermeate
Enabling biomanufacturing by improving its economics with light.
Doubling fermentation yields with 1% of the capital expenditure
Kevin Xu, PhD, CEO & Co-Founder
"Imagine a world where we produce chemicals with 80% fewer GHG emissions, grow food using just 1/10th of the land and water, all without increasing costs for consumers. Fermeate's technology can get us there, and this is a drop-in solution to existing fermentation facilities."
Fermeate has raised $450,000 from SOSV's IndieBio, the Genesis Consortium, and others.
Fermeate
Kevin Xu, PhD, CEO & Co-Founder
"Imagine a world where we produce chemicals with 80% fewer GHG emissions, grow food using just 1/10th of the land and water, all without increasing costs for consumers. Fermeate's technology can get us there, and this is a drop-in solution to existing fermentation facilities."
Fermeate has raised $450,000 from SOSV's IndieBio, the Genesis Consortium, and others.
Minutia
Pioneering a functional cure for T1D which can replace all these injections with one simple implant in the forearm.
Proof of principle of MN01 demonstrated Phase 1/2 UCSF trial

A functional cure for Type I Diabetes which does not require systemic immunosuppressants or an invasive transplant procedure, plus built-in safety monitoring and kill switch functionalities.

Katy DIgovich, CEO & Co-Founder
"Developing a functional cure for type 1 diabetes using a simple out-patient procedure, de-risked with promising proof of concept data from a phase 1/2 clinical trial."
Minutia has raised $6,500,000 from SOSV's IndieBio and others.
Minutia
Katy DIgovich, CEO & Co-Founder
"Developing a functional cure for type 1 diabetes using a simple out-patient procedure, de-risked with promising proof of concept data from a phase 1/2 clinical trial."
Minutia has raised $6,500,000 from SOSV's IndieBio and others.
Ceal
Improving power plant efficiency while sequestering CO2.
Removing over 0.5Mt CO2 / year per 1 GW power plant – at a cost of $30/ton CO2

Ceal, a carbon dioxide removal (CDR) company, is paving the way for a Net-Zero environment using the most energy-efficient technology ready to scale.
Using its proprietary technology, Ceal’s innovative process utilizes the existing infrastructure of industrial facilities to provide the cheapest gigaton-scale CDR operation. The process is additive- and emission-free, and non-reliant upon the carbon market.
In a highly efficient single-step, Ceal captures and sequesters atmospheric CO2 dissolved in seawater into industry-essential minerals, while providing soft water for various uses. Thus, enabling major cost savings and substantial new revenues for its customers. Ceal’s solution reduces the carbon footprint of the industrial facility, its marine pollution of hazardous chemicals, and simplifies its operation.
Ceal – more than just carbon dioxide removal. We heal the world.

Mati Shani, CEO & Co-Founder
"Scaling CDR must be financially viable. That is why our solution not only removes atmospheric CO2 but it saves money to our customers and provides them with a huge new revenue stream."
Ceal has raised $550,000from SOSV's IndieBio, Genesis Consortium, and others.
Ceal
Mati Shani, CEO & Co-Founder
"Scaling CDR must be financially viable. That is why our solution not only removes atmospheric CO2 but it saves money to our customers and provides them with a huge new revenue stream."
Ceal has raised $550,000from SOSV's IndieBio, Genesis Consortium, and others.
DisperseBio
Tackling a $100B+ issue with the most potent anti-biofouling agent, which is predicated on dispersing instead of killing the bacteria.
2 g of their anti-fouling agent can protect the entire hull of a ship (2000m^2 of wet surface area).

Peptide-based solution that disrupts the growth of biofilms by activating the microbe’s natural self biofilm dispersion pathway

Amir Zlotkin, PhD, CEO & Founder
"We want to empower a future beyond the anti-microbial solutions used today to fight biofilms. Fighting superbugs creates a vicious cycle where they become even more resistant and cause more harm to industry and to our health. Disperse will break this vicous cycle."
Disperse Bio has raised $300,000 from SOSV's IndieBio and others.
DisperseBio
Amir Zlotkin, PhD, CEO & Founder
"We want to empower a future beyond the anti-microbial solutions used today to fight biofilms. Fighting superbugs creates a vicious cycle where they become even more resistant and cause more harm to industry and to our health. Disperse will break this vicous cycle."
Disperse Bio has raised $300,000 from SOSV's IndieBio and others.
Metabolic Psychiatry Labs
Mental health care with metabolic therapy.
Coined the term "metabolic psychiatry" and opened the first dedicated clinic for metabolic psychiatry

Treating serious mental illness and metabolic sickness through food, real-time data and a remote clinical care team.

Shebani Sethi, MD, CEO & Founder
"Mental health isn’t just about the (CNS) brain—it’s also about the (Periphery) body - they are connected. In medicine, we are so focused on certain organs, we oftentimes forget the relationships. Metabolism fuels and shapes brain function, resilience, and recovery, redefining how we approach psychiatric care."
Metabolic Psychiatry Labs has raised $1,500,000 from SOSV's IndieBio and others.
Metabolic Psychiatry Labs
Shebani Sethi, MD, CEO & Founder
"Mental health isn’t just about the (CNS) brain—it’s also about the (Periphery) body - they are connected. In medicine, we are so focused on certain organs, we oftentimes forget the relationships. Metabolism fuels and shapes brain function, resilience, and recovery, redefining how we approach psychiatric care."
Metabolic Psychiatry Labs has raised $1,500,000 from SOSV's IndieBio and others.
SynPlexity
Synplexity makes lots of custom-sequence DNA, cheaper, longer, and more numerous than anybody else.
Enabling up to 1500x the scalability of current technologies

SynPlexity prints massively parallel amounts of DNA sequences – longer and cheaper than anything else. SynPlexity’s tech will unlock new levels of experimentation and training data for synthetic biology and generative protein AI.

Craig Stolarczyk, CEO & Co-Founder
"Unlocking biology requires harnessing the full power of high-throughput screening and machine learning. We eliminate the bottlenecks, delivering synthetic genes at a scale, 100,000 to 1,000,000 genes, at a price that makes ambitious experiments feasible."
Synplexity has raised $520,000 from SOSV's IndieBio and others.
SynPlexity
Craig Stolarczyk, CEO & Co-Founder
"Unlocking biology requires harnessing the full power of high-throughput screening and machine learning. We eliminate the bottlenecks, delivering synthetic genes at a scale, 100,000 to 1,000,000 genes, at a price that makes ambitious experiments feasible."
Synplexity has raised $520,000 from SOSV's IndieBio and others.
Phytogenesis
The first product to help all farmers prevent yield losses from the world's fast-evolving pathogens.
Dropped their active ingredient cost from $1,000/ acre to $3/ acre in the last few months with their target set at under $1.

Commercializing newly discovered molecules that induce innate plant defense mechanisms with the goal of greatly reducing, or even eliminating, the need for chemical pesticides, fungicides, and likely insecticides.

Garret Bain, CEO & Co-Founder
"Healthier crops need fewer chemicals and less intervention by farmers. With just one application, we harness the plants’ innate immune ability to deliver broad-spectrum protection against a range of pathogens and diseases that lasts the entire growing season."
Phytogenesis has raised $3,200,000 from SOSV's IndieBio, the Genesis Consortium, and others.
Phytogenesis
Garret Bain, CEO & Co-Founder
"Healthier crops need fewer chemicals and less intervention by farmers. With just one application, we harness the plants’ innate immune ability to deliver broad-spectrum protection against a range of pathogens and diseases that lasts the entire growing season."
Phytogenesis has raised $3,200,000 from SOSV's IndieBio, the Genesis Consortium, and others.